^
Association details:
| Biomarker: | miR-138 underexpression + miR-497 overexpression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Plasma exosome microRNAs in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab: Potential biomarkers of response to therapy.
Published date:
02/08/2021
Excerpt:
We sought to quantify plasma exosome microRNAs (miRNAs) and correlate with response to first line nivolumab and ipilimumab (N/I) to potentially serve as such a biomarker....the only patient to achieve a complete response had the lowest expression of miR138 and the highest expression of miR497.
DOI:
10.1200/JCO.2021.39.6_suppl.338